The article highlights the journey of Fernando Goldsztein and his son Frederico, a personal experience that led to the creation of an initiative that now brings together scientists, families, and institutions in a global effort to develop new therapies for medulloblastoma, a rare and aggressive pediatric brain tumor.
By sharing the origins of the MBI, VivaBem underscores both the human impact and the scientific reach of this cause: a network that crosses borders, connects leading research centers, and accelerates the pathways that allow children around the world to access more advanced and promising treatments.
This national recognition reinforces the strength of a mission that began in Brazil and has since become a bridge between cutting-edge research, international collaboration, and real hope for thousands of families.
Read the full article on VivaBem/UOL.
We remain steadfast in our commitment to accelerating the cure through science, collaboration, and purpose.
